Articles » Active Bacterial Core Surveillance: DBMD

Active Bacterial Core Surveillance: DBMD

Article title: Active Bacterial Core Surveillance: DBMD

Conditions: Group A streptococcus, Group B streptococcus, Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae

Source: DBMD

---

Active Bacterial Core Surveillance (ABCs)

  See ABCs Homepage

 

Purpose	To determine the incidence and epidemiologic characteristics of invasive bacterial disease, determine molecular epidemiologic patterns and microbiologic characteristics for isolates causing disease, and to provide an infrastructure for nested special studies to identify risk factors and to evaluate prevention policies.
Pathogens	Group A streptococcus, Group B streptococcus, Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae.
Population	Approximately 34.2 million, some or all counties in the following states: California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New York, Oregon, and Tennessee.
Case Definition	Isolation of one of the five bacterial pathogens from a normally sterile site in a resident of the surveillance population.
Methodology	Active laboratory-based surveillance of invasive disease in area residents. Collection of demographic, clinical data, and bacterial isolates. Regular laboratory audits to assess completeness of active surveillance and detect additional cases. Collaboration between state health departments, academic investigators, and CDC.
Disease Burden	Group A streptococcus -- 3.2 cases per 100,000; estimated 9,000 cases and 1,000 deaths annually in the United States Group B streptococcus -- 6.9 cases per 100,000; estimated 18,900 cases and 1,900 deaths annually in the United States Haemophilus influenzae -- 1.3 cases per 100,000; estimated 3,400 cases and 625 deaths annually in the United States Neisseria meningitidis -- 0.8 cases per 100,000; estimated 2,200 cases and 275 deaths annually in the United States Streptococcus pneumoniae -- 21.9 cases per 100,000; estimated 60,000 cases and 6,700 deaths annually in the United States
Challenges	Increasing antimicrobial resistance; aging population.
Opportunities	Measuring impact of newly licensed pneumococcal conjugate vaccine on disease and drug resistance; harnessing molecular techniques to characterize bacterial isolates.
	December 2001

 
 
 

Enter your search terms Submit search form
Search The Web Search wrongdiagnosis.com

Research
mistakes, errors,
and misdiagnosis
of major diseases.

Check one
or many
symptoms